Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Differential type 2 diabetes therapy based on pathophysiological aspects].

M Hanefeld1, S Fischer

  • 1Zentrum für Klinische Studien, GWT-TU Dresden. hanefeld@gwt-tud.de

Therapeutische Umschau. Revue Therapeutique
|September 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2016
Same author

Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2016
Same author

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).

Diabetes, obesity & metabolism·2015
Same author

Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation.

Diabetes & metabolism·2014
Same author

[Modern medical treatment of type 2 diabetes].

Deutsche medizinische Wochenschrift (1946)·2014
Same author

[Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2].

Herz·2014
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Type 2 Diabetes treatment varies based on hyperglycemia type. Isolated fasting hyperglycemia (IFH) responds to metformin, while isolated postprandial hyperglycemia (IPH) benefits from prandial antidiabetics, guiding individualized oral diabetes therapies.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Clinical Medicine

Context:

  • Type 2 Diabetes Mellitus (T2DM) presents with insulin secretion deficits and resistance.
  • Hyperglycemia classification includes isolated fasting (IFH), isolated postprandial (IPH), and combined (CH).
  • IFH is linked to insulin resistance, while IPH indicates a more significant insulin deficit.

Purpose:

  • To outline a differential therapy approach for T2DM using oral antidiabetic drugs (OADs).
  • To guide OAD selection based on hyperglycemia type (IFH vs. IPH), BMI, comorbidities, and age.
  • To emphasize individualized, pathophysiology-based treatment over stepwise algorithms.

Summary:

  • Metformin and long-acting sulfonylureas benefit IFH patients.
  • Prandial antidiabetics (e.g., AGI, nateglinide, repaglinide) are suitable for IPH.

Related Experiment Videos

  • Metformin and AGI aid weight reduction without hyperglycemia risk; prandial secretagogues offer lower hypoglycemia and weight gain risks compared to sulfonylureas.

    • Impact:

    • Individualized therapy optimizes T2DM management by considering patient-specific factors.
    • This approach can improve adherence and treatment outcomes in diverse patient populations.
    • Facilitates rational combination therapy selection when monotherapy is insufficient.